Objectif Annually, malaria causes 200 million clinical cases and more than half a million deaths. Works carried out more than 40 years ago demonstrated that a malaria vaccine offering sterile protective immunity in humans was possible, but the efforts to develop a modern, recombinant ‘subunit’ malaria vaccine only confer short term protection against clinical malaria in 35-50% of recipients. Several evidences support the presence of foreign short N-glycans and other minor glycosylations in the surfaces of the parasite, Plasmodium faciparum, the causative agent of malaria. In addition, recent studies show that Plasmodium sporozoites present also unknown α-galactose containing antigens in their surface and that antibodies against them provide sterile protection against malaria in mice. We propose to completely characterize the protein glycosylation present in the surface of the extracellular sporozoites, that travel from the mosquito to the liver, and merozoites, that invade human erythrocytes. We will use different quasi-targeted glycoproteomic approaches, based on the expected simplicity and low variability of these glycosylations in the parasite surface and their affinity to well characterized lectins. The investigation of these uncommon parasitic glycosylations may expose an unexpected Achilles’ heel in the Plasmodium parasite that could be exploited to halt sporozoite development and/or stop merozoite invasion and induce protection against malaria, mimicking what has already been achieved using carbohydrate-protein conjugate vaccines against bacterial infections. Champ scientifique medical and health scienceshealth sciencesinfectious diseasesmalariamedical and health scienceshealth sciencespublic healthmedical and health sciencesbasic medicineimmunologyimmunisationmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesnatural sciencesbiological scienceszoologyinvertebrate zoology Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Thème(s) MSCA-IF-2015-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF) Appel à propositions H2020-MSCA-IF-2015 Voir d’autres projets de cet appel Régime de financement MSCA-IF-EF-ST - Standard EF Coordinateur FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA Contribution nette de l'UE € 158 121,60 Adresse C ROSSELLO 132 PLANTA 05 08036 Barcelona Espagne Voir sur la carte Région Este Cataluña Barcelona Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 158 121,60
